Pharmacokinetics of mono-3′- and mono-4′-0-(β-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 58, Issue 6, 2002, Pages 395-402

  Kienzler, J L ^a,b   Sallin, D ^a,b   Schifflers, M H ^a,b   Ghika, A ^a,b  

^a Department of Clinical Pharmacology   (Switzerland)

^b Department of Clinical Research ^*  (Switzerland)

Author keywords

Hydroxyethylrutosides; Pharmacokinetics

Indexed keywords

3' O (BETA HYDROXYETHYL)QUERCETIN; 4' O (BETA HYDROXYETHYL)QUERCETIN; MONOXERUTIN; RUTOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYETHYLRUTOSIDE; MALE; MIDDLE AGED; POWDERS;

EID: 0036378983     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0472-3     Document Type: Article

References (22)

1. Poynard T, Valterio C (1994) Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 23:244-250
2. Burnand KG, Powell S, Bishop C, Stacey M, Pulvertaft T (1989) Effect of Paroven on skin oxygenation in patients with varicose veins. Phlebology 4:15-22
3. Cloarec M, Clément R, Griton P (1996) A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology 11:76-82
4. 2 measurements, leg volumetry and ambulatory venous pressure measurements. Vasa 18:146-151
5. Diebschlag W, Nocker W, Lehmacher W, Rehn D (1994) A clinical comparison of two doses of O-(β-hydroxyethyl)-ruto-sides (oxerutins) in patients with chronic venous insufficiency. J Pharm Med 4:7-14
6. Hackett AM, Griffiths LA, Luyckx AS, Cauwenberge H van (1976) Metabolism of hydroxyethylrutosides (HR) -metabolism of [14C]-HR in man. Arzneimittelforschung 26:925-928
7. Bokkenheuser VD, Shackleton CHL, Winter J (1987) Hydrolysis of dietary flavonoid glycosides by strains of intestinal bacteroides from humans. Biochem J 248:953-956
8. Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJC, Morgan MRA, Williamson G (1998) Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity. FEBS Lett 436:71-75
9. Day AJ, Canada FJ, Diaz JC, Kroon PA, Mclauchlan R, Faulds CB, Plumb GW, Morgan MRA, Williamson G (2000) Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett 468:166-170
10. Barrow A, Griffiths LA (1974) Metabolism of the hydroxy-ethylrutosides III - The fate of orally administered hydroxy-ethylrutosides in laboratory animals - Metabolism by rat intestinal microflora in vitro. Xenobiotica 4:743-754
11. Balant LP, Wermeille M, Griffiths LA (1984) Metabolism and pharmacokinetics of hydroxyethylated rutosides in animals and man. Drug Metabol Drug Interact 5:1-24
12. Steinijans VW, Hauschke D (1990) Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28:105-110
13. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In: Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 409-417
14. Gugler R, Leschik M, Dengler HJ (1975) Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 9:229-234
15. Unkauf M, Rehn D, Klinger J, Motte S de la, Großmann K (1996) Investigation of the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittelforschung (Sonderdruck) 46:478-482
16. Neumann HAM, Broek MJTB van den, Crombag NH, Dikland WJ, Wit RFE de, Vermander F, Bersaques J de, Gjoeres JE, Hagenfeldt I, Hallbook T, Wikstrom K, Landanyi E, Ruckley CV (1996) Evaluation of O-(β-hydroxyethyl-) rutosides in the prevention of the breakdown of venous ulcers. A longterm international multicentre controlled clinical trial. Scripta Phlebologica 4:55-63
17. Tan HSI, Mowery PJ, Ritschel WA, Neu C (1978) Spectrophotofluorometric analysis of 3′,4′,7-tris[O-(beta-hydroxyethyl)]rutoside in urine. J Pharm Sci 67:1142-1144
18. Barrow A, Griffiths LA (1974) Metabolism of the hydroxyethylrutosides II excretion and metabolism of 3, 4, 7-tri-O-(β-hydroxyethyl)rutoside and related compounds in laboratory animals after parenteral administration. Xenobiotica 4:1-16
19. Hackett AM, Griffiths LA (1977) Enterohepatic cycling of o-(β-hydroxyethyl)-rutosides and their biliary metabolites in the rat. Experiencia 33:161-163
20. Williamson G, Plumb GW, Uda Y, Price KR, Rhodes MJC (1996) Dietaryquercetin glycosides: antioxidant activity and induction of the anticarcinogenic phase II marker enzyme quinone reductase in Hepalclc7 cells. Carcinogenesis 17:2385-2387
21. DuPont MS, Gee JM, Price KR Johnson IT (1999) Gut 44[Suppl 1]:A130
22. Erlund I, Kosonen T, Alfthan G, Mäenpää J et al. (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56:545-553